摘要
目的分析重组人干扰素α-2b喷雾剂治疗儿童急性上呼吸道感染的疗效。方法选择2017年1月至2018年12月梧州市中医医院儿科就诊且住院治疗的急性上呼吸道感染患儿200例,其中男性108例,女性92例;年龄0.5~7.0岁,平均年龄(2.90±1.08)岁;身高65.4~124.3cm,平均身高(96.09±11.56)cm;体质量8.3~24.4kg,平均体质量(15.35±3.76)kg;发病时间0.5~4.0d,平均发病时间(1.08±0.37)d。随机分为观察组100例和对照组100例。观察组使用重组人干扰素α-2b喷雾剂,对照组采用利巴韦林喷剂。分析和比较2组患儿治疗效果、不良反应及临床指标。结果经过治疗,观察组患儿有效率为89.0%,明显高于对照组(77.0%)(P<0.05);观察组患儿体温复常时间[(1.76±0.75)d]、咳嗽消失时间[(1.83±0.85)d]、鼻塞流涕消失时间[(2.08±0.91)d]、咽部疼痛消失时间[(2.25±0.78)d]均明显短于对照组(P<0.01)。观察组患儿白细胞(WBC)[(11.18±1.90)×10^9/L]低于对照组[(12.85±2.43)×10^9/L](P<0.01);观察组患儿肌酸激酶同工酶(CK-MB)[(15.84±4.69)U/L]显著低于对照组[(17.88±4.87)U/L](P<0.01)。观察组患儿不良反应发生率(2.0%)低于对照组(4.0%),但差异无统计学意义(P>0.05)。结论重组人干扰素α-2b喷雾剂治疗患儿急性上呼吸道感染疗效显著,有效改善患儿临床症状和体征,提高机体免疫功能,保护心肌。
Objective To analyze the efficacy of recombinant interferon α-2b spray for treatment of acute upper respiratory tract infection in children.Methods From January 2017 to December 2018,200 hospitalized children of acute upper respiratory tract infection were enrolled,which included 108 males and 92 females;aged 0.5 - 7.0 years old with mean age of (2.90 ± 1.08) years old;body height was 65.4 - 124.3 cm with mean body height of (96.09 ± 11.56) cm;body mass was 8.3 - 24.4 kg with mean body mass of (15.35 ± 3.76) kg;onset time was 0.5 - 4.0 days with mean onset time of (1.08 ± 0.37) days.All of them were randomly divided into observation group(n = 100) and control group(n = 100).Recombinant human interferon alpha- 2b spray and Ribavirin spray were used in observation group and control group,respectively.The treatment effects,adverse reactions and clinical indicators between 2 groups were analyzed and compared.Results After treatment,the effective rate of observation group was 89.0 %,which was significantly higher than that of control group(77.0 %)(P < 0.05).The normal temperature of observation group[(1.76 ± 0.75) days],disappearance time of cough[(1.83 ± 0.85) days],nasal congestion[(2.08 ± 0.91) days] and pharyngeal pain[(2.25 ± 0.78) days] were significantly shorter than those of control group(P < 0.01).The white blood cells(WBC) in observation group[(11.18 ± 1.90)× 10^9 /L] were lower than that of control group[(12.85 ± 2.43)× 10^9 /L](P < 0.01);the creatine kinase isoenzyme(CK-MB) of observation group[(15.84 ± 4.69) U/L] was significantly lower than the control group[(17.88 ± 4.87) U/L](P < 0.01).The adverse reaction rate of observation group(2.0 %) was lower than that of control group(4.0 %) without statistically significance(P > 0.05).Conclusion It is demonstrated that recombinant interferon α-2b spray is effective in treatment of children with acute upper respiratory tract infection,which could improve clinical symptoms and signs,immune function,and protect myocardium of children.
作者
陈青
钟斌
李研
岑杨成
李明明
廖泽辉
潘娟
陶园
唐兰
CHEN Qing;ZHONG Bin;LI Yan;CEN Yang -cheng;LI Ming -ming;LIAO Ze -hui;PAN Juan;TAO Yuan;TANG Lan(Department of Pediatrics,Chinese Traditional Medicine Hospital of Wuzhou,Wuzhou 543003,Guangxi,China)
出处
《生物医学工程与临床》
CAS
2019年第4期462-466,共5页
Biomedical Engineering and Clinical Medicine
基金
2017年度广西中医药大学自然科学研究项目(2017MS041)
关键词
急性上呼吸道感染
儿童
重组人干扰素Α-2B
治疗效果
acute upper respiratory tract infection
children
recombinant interferon α-2b
therapeutic effect
